BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,096 filers reported holding BAXTER INTL INC in Q4 2020. The put-call ratio across all filers is 0.87 and the average weighting 0.2%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,239,369 | -17.3% | 138,828 | -0.2% | 0.03% | -12.8% |
| Q2 2023 | $6,338,672 | +12.7% | 139,128 | +0.4% | 0.04% | +5.4% |
| Q1 2023 | $5,622,752 | -19.5% | 138,628 | +1.2% | 0.04% | -24.5% |
| Q4 2022 | $6,984,317 | -4.9% | 137,028 | +0.5% | 0.05% | -9.3% |
| Q3 2022 | $7,343,000 | -15.8% | 136,328 | +0.4% | 0.05% | -10.0% |
| Q2 2022 | $8,724,000 | -10.9% | 135,828 | +7.5% | 0.06% | +5.3% |
| Q1 2022 | $9,795,000 | -9.5% | 126,328 | +0.2% | 0.06% | 0.0% |
| Q4 2021 | $10,821,000 | +7.2% | 126,055 | +0.4% | 0.06% | 0.0% |
| Q3 2021 | $10,098,000 | -0.8% | 125,555 | -0.7% | 0.06% | -5.0% |
| Q2 2021 | $10,180,000 | -4.8% | 126,455 | -0.2% | 0.06% | -11.8% |
| Q1 2021 | $10,691,000 | +3.7% | 126,755 | -1.3% | 0.07% | -2.9% |
| Q4 2020 | $10,307,000 | -0.8% | 128,455 | -0.5% | 0.07% | -15.7% |
| Q3 2020 | $10,387,000 | -7.2% | 129,155 | -0.6% | 0.08% | -15.3% |
| Q2 2020 | $11,189,000 | +17.7% | 129,955 | +11.0% | 0.10% | -6.7% |
| Q1 2020 | $9,509,000 | -7.9% | 117,122 | -5.2% | 0.10% | +23.5% |
| Q4 2019 | $10,329,000 | -3.8% | 123,522 | +0.7% | 0.08% | -12.4% |
| Q3 2019 | $10,734,000 | +15.3% | 122,722 | +8.0% | 0.10% | +15.5% |
| Q2 2019 | $9,306,000 | -16.7% | 113,622 | -17.3% | 0.08% | -6.7% |
| Q1 2019 | $11,166,000 | +19.7% | 137,322 | -3.1% | 0.09% | +7.1% |
| Q4 2018 | $9,328,000 | -18.3% | 141,722 | -4.3% | 0.08% | +1.2% |
| Q3 2018 | $11,411,000 | +6.0% | 148,022 | +1.5% | 0.08% | -2.4% |
| Q2 2018 | $10,767,000 | +13.1% | 145,822 | -0.3% | 0.08% | +10.4% |
| Q1 2018 | $9,517,000 | +0.2% | 146,322 | -0.4% | 0.08% | +2.7% |
| Q4 2017 | $9,497,000 | -0.5% | 146,922 | -3.4% | 0.08% | -2.6% |
| Q3 2017 | $9,546,000 | -1.6% | 152,122 | -5.1% | 0.08% | +5.5% |
| Q2 2017 | $9,706,000 | +17.3% | 160,322 | +0.4% | 0.07% | +14.1% |
| Q1 2017 | $8,278,000 | -11.3% | 159,622 | -24.1% | 0.06% | -13.5% |
| Q4 2016 | $9,330,000 | -11.4% | 210,422 | -4.8% | 0.07% | -10.8% |
| Q3 2016 | $10,525,000 | +0.5% | 221,114 | -4.5% | 0.08% | +1.2% |
| Q2 2016 | $10,474,000 | +35.2% | 231,614 | +22.8% | 0.08% | +32.3% |
| Q1 2016 | $7,749,000 | +8.5% | 188,639 | +0.8% | 0.06% | +12.7% |
| Q4 2015 | $7,139,000 | +10.4% | 187,139 | -5.0% | 0.06% | +10.0% |
| Q3 2015 | $6,469,000 | -91.5% | 196,939 | -81.9% | 0.05% | -90.6% |
| Q2 2015 | $76,296,000 | +432.1% | 1,091,039 | +421.2% | 0.53% | +430.0% |
| Q1 2015 | $14,340,000 | -12.4% | 209,339 | -6.2% | 0.10% | -7.4% |
| Q4 2014 | $16,361,000 | +2.7% | 223,239 | +0.5% | 0.11% | -2.7% |
| Q3 2014 | $15,936,000 | -0.9% | 222,039 | -0.1% | 0.11% | -0.9% |
| Q2 2014 | $16,075,000 | -1.5% | 222,339 | +0.3% | 0.11% | -8.9% |
| Q1 2014 | $16,316,000 | +6.3% | 221,739 | +0.5% | 0.12% | +5.1% |
| Q4 2013 | $15,345,000 | +5.8% | 220,639 | -0.0% | 0.12% | -7.9% |
| Q3 2013 | $14,500,000 | -4.9% | 220,739 | +0.3% | 0.13% | -9.3% |
| Q2 2013 | $15,249,000 | – | 220,139 | – | 0.14% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SECTOR GAMMA AS | 713,500 | $49,895,000 | 12.74% |
| Veritas Asset Management LLP | 7,636,450 | $534,017,000 | 7.53% |
| FIRST NEW YORK SECURITIES LLC /NY | 154,158 | $10,780,269,000 | 5.40% |
| Gabalex Capital Management LLC | 200,000 | $14,981,000 | 5.39% |
| Veritas Investment Management LLP | 291,825 | $18,816,000 | 5.32% |
| Tweedy, Browne Co LLC | 2,543,966 | $177,900,000 | 4.91% |
| York Capital Management Global Advisors, LLC | 8,074,375 | $564,641,000 | 4.78% |
| First Fiduciary Investment Counsel, Inc. | 270,675 | $18,928,000 | 4.10% |
| SCHARF INVESTMENTS, LLC | 2,247,225 | $157,148,000 | 4.03% |
| Osher Van de Voorde Investment Management | 96,235 | $6,730,000 | 3.91% |